Occult transthyretin cardiac amyloid in severe calcific aortic stenosis

Circulation: Cardiovascular Imaging

Volumn 9, Issue 8, 2016, Pages

  Treibel, Thomas A ^a,b   Fontana, Marianna ^a,b   Gilbertson, Janet A ^b   Castelletti, Silvia ^a   White, Steven K ^a,b   Scully, Paul R ^a   Roberts, Neil ^a   Hutt, David F ^b   Rowczenio, Dorota M ^b   Whelan, Carol J ^d   Ashworth, Michael A ^c   Gillmore, Julian D ^b   Hawkins, Philip N ^b   Moon, James C ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d NONE

Author keywords

aortic stenosis, calcific; aortic valve stenosis; biopsy; Congo red; mass spectrometry

Indexed keywords

AMYLOID; BUTEDRONATE TECHNETIUM TC 99M; CONGO RED; GADOTERATE MEGLUMINE; PREALBUMIN;

ADULT; AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE SCINTISCANNING; CALCIFIC AORTIC STENOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HEART SCINTISCANNING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIMODAL IMAGING; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PHENOTYPE; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL MORTALITY; SURGICAL PATIENT; TRANSTHORACIC ECHOCARDIOGRAPHY; WILD TYPE; ADVERSE EFFECTS; AMYLOID NEUROPATHIES, FAMILIAL; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOPSY; CARDIAC MUSCLE; CARDIOMYOPATHIES; CHEMISTRY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; ENGLAND; GENETIC PREDISPOSITION; GENETICS; HEART VALVE REPLACEMENT; KAPLAN MEIER METHOD; MORTALITY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOPSY; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LONDON; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY; MUTATION; MYOCARDIUM; PHENOTYPE; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84983527096     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.116.005066     Document Type: Article

References (38)

1. Fact sheet no 310:Global Burden of Disease update World Health Organization. 2008
2. Lindroos M, Kupari M, Heikkilä J, Tilvis R, Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993 21 1220 1225
3. Longhi S, Lorenzini M, Gagliardi C, Milandri A, Marzocchi A, Marrozzini C, Saia F, Ortolani P, Biagini E, Guidalotti PL, Leone O, Rapezzi C, Coexistence of Degenerative Aortic Stenosis and Wild-Type Transthyretin-Related Cardiac Amyloidosis. JACC Cardiovasc Imaging 2016 9 325 327. doi: 10.1016/j.jcmg.2015.04.012
4. Merlini G, Bellotti V, Molecular mechanisms of amyloidosis. N Engl J Med 2003 349 583 596. doi: 10.1056/NEJMra023144
5. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH, Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005 165 1425 1429. doi: 10.1001/archinte.165.12.1425
6. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S, Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009 120 1203 1212. doi: 10.1161/CIRCULATIONAHA.108.843334
7. Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitkänen P, Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983 75 618 623
8. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L, Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008 40 232 239. doi: 10.1080/07853890701842988
9. Nietlispach F, Webb JG, Ye J, Cheung A, Lichtenstein SV, Carere RG, Gurvitch R, Thompson CR, Ostry AJ, Matzke L, Allard MF, Pathology of transcatheter valve therapy. JACC Cardiovasc Interv 2012 5 582 590. doi: 10.1016/j.jcin.2012.03.012
10. Castaño A, Bokhari S, Maurer MS, Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis? J Am Coll Cardiol 2015 65 311 312. doi: 10.1016/j.jacc.2014.09.084
11. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC, Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014 7 157 165. doi: 10.1016/j.jcmg.2013.10.008
12. Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon JC, Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology 2015 277 388 397. doi: 10.1148/radiol.2015141744
13. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC, Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 2015 132 1570 1579. doi: 10.1161/CIRCULATIONAHA.115.016567
14. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, Lane T, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD, Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014 15 1289 1298. doi: 10.1093/ehjci/jeu107
15. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ, Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013 2 e000098. doi: 10.1161/JAHA.113.000098
16. Benson MD, Pandey S, Witchell D, Jazayeri A, Siwkowski A, Monia B, Kluve-Beckerman B, Antisense oligonucleotide therapy for TTR amyloidosis. Amyloid 2011 18 suppl 1 60. doi: 10.3109/13506129.2011.574354021
17. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quiñones M, EAE/ASE Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. Eur J Echocardiogr 2009 10 1 25. doi: 10.1093/ejechocard/jen303
18. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, Thomas JD, Merlino JD, Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009 103 411 415. doi: 10.1016/j.amjcard.2008.09.102
19. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson 2008 10 35. doi: 10.1186/1532-429X-10-35
20. Piechnik SK, Ferreira VM, Dall?Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD, Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010 12 69. doi: 10.1186/1532-429X-12-69
21. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB, Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013 15 92. doi: 10.1186/1532-429X-15-92
22. King DL, El-Khoury Coffin L, Maurer MS, Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography. J Am Coll Cardiol 2002 40 325 329
23. Carroll JD, Gaasch WH, McAdam KP, Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982 49 9 13
24. Puchtler H, Sweat F, Amidoblack as a stain for hemoglobin. Arch Pathol 1962 73 245 249
25. Gilbertson JA, Theis JD, Vrana JA, Lachmann H, Wechalekar A, Whelan C, Hawkins PN, Dogan A, Gillmore JD, A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 2015 68 314 317. doi: 10.1136/jclinpath-2014-202722
26. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A, Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009 114 4957 4959. doi: 10.1182/blood-2009-07-230722
27. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005 46 1076 1084. doi: 10.1016/j.jacc.2005.05.073
28. Kyle RA, Gertz MA, Linke RP, Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. Am J Clin Pathol 1992 97 250 253
29. Monticelli FC, Kunz SN, Keller T, Bleiziffer S, Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve implantation. J Card Surg 2014 29 623 624. doi: 10.1111/jocs.12305
30. Chimenti C, Frustaci A, Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 2013 128 1531 1541. doi: 10.1161/CIRCULATIONAHA.13.001414
31. Allen RD, Edwards WD, Tazelaar HD, Danielson GK, Surgical pathology of subaortic septal myectomy not associated with hypertrophic cardiomyopathy: a study of 98 cases (1996-2000). Cardiovasc Pathol 2003 12 207 215
32. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK, Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol 2003 12 149 158
33. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR, Mereuta OM, Theis JD, Dogan A, Edwards WD, Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol 2014 114 1396 1399. doi: 10.1016/j.amjcard.2014.07.058
34. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM, Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014 2 113 122. doi: 10.1016/j.jchf.2013.11.004
35. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015 36 2585 2594. doi: 10.1093/eurheartj/ehv338
36. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS, (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013 6 195 201. doi: 10.1161/CIRCIMAGING.112.000132
37. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD, A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid 2005 12 127 130. doi: 10.1080/13506120500107162
38. Buxbaum J, Jacobson DR, Tagoe C, Alexander A, Kitzman DW, Greenberg B, Thaneemit-Chen S, Lavori P, Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol 2006 47 1724 1725. doi: 10.1016/j.jacc.2006.01.042